Triazole ACC inhibitors and uses thereof

A compound of formula I:

• or a pharmaceutically acceptable salt or agriculturally acceptable salt thereof, wherein:
• X is —O—, —S—, or —NR—;
• R1 is hydrogen, C1-4 aliphatic optionally substituted with 1-4 halogen, —OR, —SR, —N(R)2, —N(R)C(O)R, —C(O)N(R)2, —N(R)C(O)N(R)2, —N(R)C(O)OR, —OC(O)N(R)2, —N(R)S(O)2R, —S(O)2N(R)2, —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, or —S(O)2R;
• each instance of R2, R6, R7, and R8 is independently oxo;
• halogen;
• —CN;
• —OR;
• —Ra, —SR;
• —N(R)2;
• —N(R)C(O)R;
• —C(O)N(R)2;
• —N(R)C(O)N(R)2;
• —N(R)C(O)OR;
• —OC(O)N(R)2;
• —N(R)S(O)2R;
• —S(O)2N(R)2;
• —C(O)R;
• —C(O)OR;
• —OC(O)R;
• —S(O)R;
• or —S(O)2R;
• each R is independently hydrogen or Ra;
• each Ra is independently an optionally substituted group selected from C1-6 aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• L1 is a covalent bond;
• a 1-6 membered straight or branched bivalent hydrocarbon chain;
• cyclopropylenyl;
• cyclobutylenyl;
• or oxetanylenyl;
• L2 is a covalent bond or a 1-6 membered straight or branched bivalent hydrocarbon chain;
• wherein L2 is substituted by n instances of R9;
• R3 is —OR, —C(O)OR, —N(R)C(O)OR, —OC(O)N(R)2, —C(O)N(R)OR, —C(O)NH2, —C(O)NHRa, C(O)N(Ra)2, or —C(O)Hy;
• Hy is a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• wherein Hy is substituted by p instances of R6;
• R4 is selected from a 3-8 membered monocyclic saturated or partially unsaturated carbocyclic ring, a 4-8 membered monocyclic saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, phenyl, an 8-10 membered bicyclic aryl ring, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• wherein R4 is substituted by q instances of R7;
• each R5 is independently hydrogen, C1-4 aliphatic, a 3-8 membered monocyclic saturated or partially unsaturated carbocyclic ring, a 4-8 membered monocyclic saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, phenyl, an 8-10 membered bicyclic aryl ring, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• wherein each R5 is substituted with r instances of R8;
• each R9 is independently oxo or —OR5;
• m is 0, 1, 2, or 3;
• n is 0, 1, or 2;
• p is 0, 1, 2, 3, or 4;
• q is 0, 1, 2, 3, 4, or 5;
• and
• r is 0, 1, 2, 3, or 4.